Ethionamide: Uses, Dosage, Side Effects & Precautions

Introduction

Ethionamide is an antibiotic medication used in the treatment of tuberculosis (TB), particularly in cases of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). It is a key component of combination therapy regimens for these resistant strains of Mycobacterium tuberculosis. Ethionamide works by inhibiting the synthesis of mycolic acids, which are essential components of the bacterial cell wall. ^[1]

Chemical Composition

Ethionamide is a yellow, crystalline powder with the chemical formula C ₈H ₁₀N ₂S and a molecular weight of 166.24 g/mol. It has a melting point of 161-165°C and is soluble in organic solvents such as ethanol and methanol. Ethionamide has a characteristic sulfide odor and is nonhygroscopic. ^{Ethionamide” target=”_blank”>[2]}

Pharmacology

Ethionamide is a prodrug that is activated by the enzyme ethA, a flavin monooxygenase. Once activated, it inhibits the enzyme InhA, which is involved in the synthesis of mycolic acids. This disruption of cell wall synthesis leads to bacterial cell death. Ethionamide is well absorbed orally, with peak plasma concentrations reached within 1-2 hours. It undergoes extensive first-pass metabolism in the liver, primarily by the CYP450 enzyme system. ^[3]

Clinical Uses

Ethionamide is primarily used in the treatment of active tuberculosis, particularly in cases of MDR-TB and XDR-TB. It is used in combination with other antitubercular medications such as pyrazinamide, isoniazid, and rifampicin. Ethionamide is considered a second-line drug and is typically reserved for cases where first-line treatments have failed or are not tolerated. ^[4]

Dosage and Administration

Ethionamide is available as oral tablets, typically in strengths of 250 mg. The recommended dosage for adults is 15-20 mg/kg/day, up to a maximum of 1 g per day, divided into 2-3 doses. The drug should be taken with food to minimize gastrointestinal side effects. Dose adjustments may be necessary in patients with liver or kidney dysfunction. The brand name for ethionamide in the United States is Trecator. ^[5]

Precautions and Contraindications

Ethionamide can cause severe and sometimes irreversible visual impairment, including blurred vision, eye pain, and loss of vision. Patients should be monitored closely for visual changes and the drug should be discontinued if vision problems occur. Ethionamide is contraindicated in patients with severe liver disease, psychosis, or hypersensitivity to the drug. It should be used with caution in patients with diabetes, alcohol abuse, or peripheral neuropathy. ^[4]

Side Effects and Adverse Reactions

Common side effects of ethionamide include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and anorexia. Neurological side effects such as dizziness, fatigue, and peripheral neuropathy can also occur. Serious adverse reactions include hepatitis, lactic acidosis, hypothyroidism, and blood dyscrasias. Patients should be monitored closely for side effects and the drug should be discontinued if severe reactions occur. ^[1]

Drug Interactions

Ethionamide can interact with a variety of medications, including antidepressants, anticonvulsants, and HIV medications. It may increase the risk of hepatotoxicity when used with other hepatotoxic drugs such as isoniazid and pyrazinamide. Ethionamide may also interfere with the absorption of other medications and should be taken at least 1 hour before or 2 hours after other drugs. ^[6]

Mechanism of Resistance

Resistance to ethionamide can develop through mutations in the ethA gene, which encodes the enzyme responsible for activating the drug. Mutations in the inhA gene, which encodes the target enzyme, can also confer resistance. Cross-resistance between ethionamide and other thioamides such as prothionamide is common. ^[3]

Guidelines and Recommendations

The World Health Organization (WHO) recommends the use of ethionamide as part of combination therapy for the treatment of MDR-TB and XDR-TB. The drug should be used under the supervision of a physician experienced in the management of these conditions. Pregnant women and children may require dose adjustments and close monitoring. Patients should be educated on the importance of adherence to the prescribed regimen to prevent the development of resistance. ^[7]

Storage and Handling

Ethionamide tablets should be stored at room temperature (20-25°C) in a tightly closed container, protected from light and moisture. The drug should be handled with caution, as it can cause irritation to the skin, eyes, and respiratory tract. Proper precautions should be taken when dispensing and administering the medication. ^[5]

Research and Development

Ongoing research is focused on developing new formulations and delivery methods for ethionamide to improve its efficacy and reduce side effects. Studies are also investigating the use of ethionamide in combination with newer antitubercular drugs such as bedaquiline and delamanid. Pharmacogenomic research is exploring the role of genetic variations in the response to ethionamide and the development of resistance. ^[8]

Regulatory Status

Ethionamide is approved by the U.S. Food and Drug Administration (FDA) for the treatment of tuberculosis. It is also approved by the European Medicines Agency (EMA) and is included in the WHO Model List of Essential Medicines. The drug is available as a generic medication and is manufactured by several pharmaceutical companies worldwide. ^[9]

Patient Education

Patients should be informed about the potential side effects of ethionamide and the importance of reporting any adverse reactions to their healthcare provider. They should be advised to take the medication with food to minimize gastrointestinal side effects and to avoid alcohol while on treatment. Patients should also be counseled on the importance of completing the full course of therapy, even if symptoms improve, to prevent the development of drug resistance. Regular follow-up visits and laboratory monitoring are essential to ensure the safety and efficacy of treatment. ^[10]